RxDoctor Payments DataLook up a doctor →

Glen Nadel, MD

Allergy & Immunology · Atlanta, GANPI 1548231400

Payments from drug & device makers

$11,990in general payments, 2019–2025

Across 660 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Sanofi$2K
  • AstraZeneca$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$990
  • Pfizer$713
  • Novartis$660
  • plus $5K from 26 others

What the payments were for

  • Food & beverage$11,81099%
  • Education$1801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,990 in reported general payments places this provider in the 70th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$51,834
Medicare patients
166
Services billed
3,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo13$674,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter187$169,547
Breo ElliptaFluticasone/Vilanterol61$30,488
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$23,292
SymbicortBudesonide/Formoterol Fumarate46$17,250
Spiriva RespimatTiotropium Bromide21$16,428
Advair HfaFluticasone Propion/Salmeterol15$6,170
Arnuity ElliptaFluticasone Furoate16$5,011
Ipratropium Bromide55$4,491
Epinephrine18$3,934
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$3,789
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,092
Azelastine Hcl75$2,110
Montelukast Sodium119$1,729
Albuterol Sulfate HfaAlbuterol Sulfate55$1,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$990$674,55313 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,637$205,046264 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,580$40,54282 claims
Boehringer IngelheimSpiriva Respimat$208$16,42821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →